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Abstract  41 
Purpose: Graves’ orbitopathy (GO) is a sight-threatening autoimmune disorder causing 42 
extraocular muscle fibrosis, upper lid retraction and eye bulging due to orbital fat expansion. 43 
These clinical features are mediated by aspects of orbital fibroblasts differentiation, including 44 
adipogenesis and fibrosis. Our previous work suggested that this dual phenotype might be a 45 
manifestation of mixed cell populations, partially linked to the expression of mesenchymal stem 46 
cell (MSC) marker CD90. We thus set out to determine whether GO orbital fibroblasts displayed 47 
MSC properties.  48 
Methods: Control and GO orbital fibroblasts previously characterised for CD90 and CD45 49 
expression were analysed by flow cytometry for classical MSC positive (CD73, CD105) and 50 
negative (CD14, CD19, HLA-DR and CD34) markers. GO fibroblasts were further tested for 51 
their ability to undergo lineage specific differentiation following standard protocols. 52 
Results: Both control and GO fibroblasts strongly expressed CD73 and CD105, with a higher 53 
percentage of positive cells and stronger expression levels in GO. Neither cell type express 54 
CD14, CD19 and HLA-DR. CD34 was expressed at low levels by 45-70% of the cells, with its 55 
expression significantly lower in GO cells. GO fibroblasts displayed features of osteogenesis 56 
(calcium deposits; BGLAP and SPARC expression), chondrogenesis (glycosaminoglycan 57 
production; SOX9 and ACAN expression), myogenesis  (α-Smooth Muscle Actin expression) 58 
and neurogenesis (β-III tubulin expression) upon differentiation. 59 
Conclusions: Our findings suggest that orbital fibroblasts contain a population of cells that fulfil 60 
the criteria defining MSC. This subpopulation may be increased in GO, possibly underlying the 61 
complex differentiation phenotype of the disease.   62 
 4
Introduction 63 
Graves’ orbitopathy (GO) is a disfiguring and potentially blinding disorder 1-3. Clinical 64 
features include expansion and fibrosis of the orbital tissues, leading to proptosis, eyelid retraction, 65 
dry eye syndrome and diplopia 4. At the cellular level, pathological changes include adipogenesis, 66 
fibrosis and hyaluronan production 5. We have developed an in vitro model for GO using primary 67 
fibroblast cultures derived from orbital fat, which uniquely allows the study of both the fibrotic and 68 
the spontaneous adipogenic phenotype of orbital fibroblasts within 3 dimensional environments 6. 69 
We have shown that GO fibroblasts retain a complex phenotype in vitro, exhibiting hyaluronan 70 
production7, adipogenesis, and increased contractile properties and sensitivity to cytokine 71 
stimulation 6. Orbital fibroblasts are known to comprise a mixed population of cell subtypes, 72 
including fibrocytes 8, and Thy1+/Thy1- populations, which have been proposed to underlie the 73 
adipogenic and contractile phenotype 6, 9. Thy1 (CD90) is a major marker of stromal and adipose 74 
derived stem cells 10-12.  The high level of Thy1 expression in orbital cells in GO, as well as the 75 
diversity of the cell phenotypes observed, suggested that GO fibroblasts may possess mesenchymal 76 
stem cell-like (MSC) characteristics. We describe here how we use cell marker expression and in 77 
vitro differentiation to further investigate the presence of a potential MSC-like population in orbital 78 
fibroblasts.   79 
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Methods 80 
Ethics Statement 81 
This study was conducted according to the principles of the Declaration of Helsinki and 82 
reviewed by the National Research Ethics Service Committee London-Bentham (REC reference 83 
number 11/LO/1170).  All participants gave their informed written consent before enrolment. 84 
 85 
Cells 86 
The 3 GO (HO1, HO2, HO3) and 3 control (CO2, CO3, CO4) orbital fibroblast lines 87 
used in this study and the clinical details of the donors have been described previously 6. Briefly, 88 
the GO lines were derived from patients with severely active disease, having undergone prior 89 
immunosuppressive steroid treatment, whilst the control samples were from patients undergoing 90 
removal of sub-conjunctival fat herniation 6. Unless otherwise stated, cells were grown in 91 
Dulbecco’s modified Eagle’s medium (DMEM, 4.5g/L L-glutamine, Life Technologies, Thermo 92 
Fischer Scientific, Paisley, UK) with the addition of 10% foetal bovine serum (FBS, Sigma-93 
Aldrich, Gillingham, UK), 100 IU/ml penicillin, 100μg/ml streptomycin (Life Technologies, 94 
Thermo Fischer Scientific, Paisley, UK), and used between passage 3 and 8. 95 
 96 
Flow cytometry 97 
Subconfluent orbital GO and control fibroblasts were trypsinised and 0.3-1x106 cells 98 
were placed in each vial and pelleted. Cells were then resuspended in 100μl of PBS with addition 99 
of unlabelled primary (CD221, Biolegend, London, UK) or PE-conjugated (CD14, CD19, CD34, 100 
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CD73, CD105, HLA-DR, and isotype controls IgG1 and IgG2, all from BioLegend, London, 101 
UK) antibodies and incubated on ice for 1 hour. For CD221, this was followed by a PBS wash 102 
and 1 hour incubation with Cy5-conjugated goat anti-rabbit antibody (Jackson Labs, Maine, 103 
USA).  Cells were washed twice with PBS, resuspended in 300μl of PBS and transferred to 104 
FACS tubes (BD Falcon, BD Biosciences, Erembodegem, Belgium). Analysis was performed 105 
using FACSCalibur (Beckton Dickinson, Oxford, UK). At least 10,000 cells were analysed per 106 
experiment, all experiments were repeated independently 3 times. The markers have been used 107 
previously to characterise multi-potent stem cells from orbital fat tissue using FACS analysis 13, 108 
14 and are known to be insensitive to trypsin treatment 15-19, with the exception of CD14 for 109 
which immunofluorescence was used to confirm the absence of staining in orbital fibroblasts not 110 
treated with trypsin (Supplementary Figure 1, Supplementary Methods and Legends). CD73 was 111 
used as a positive control for immunofluorescence on orbital fibroblasts monolayers 112 
(Supplementary Figure 2).  113 
 114 
Chondrogenic and osteogenic differentiation 115 
Chondrogenic differentiation was performed as previously described 20. Briefly, 1.25x106 116 
GO fibroblasts were centrifuged and resuspended in 1ml of Chondrocyte Differentiation Medium 117 
(ZenBio, NC, USA). 200μl of the cell suspension was dispensed per well into Nunc 96-well 118 
round bottom plates. Plates were centrifuged at 500g for 5 minutes to generate a pellet and 119 
differentiation was left to proceed for 21 days with the medium changed every other day. Alcian 120 
blue staining was used to identify chondrogenic differentiation 20. The cell pellets were fixed in 121 
formalin and embedded in paraffin. Sections were deparaffinised, and half of them were 122 
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pretreated with 0.5 mg/ml hyaluronidase (Sigma-Aldrich, Gillingham, UK) in a phosphate buffer 123 
pH 6.7. All sections were then stained with 1% alcian blue 8GX (TCS Biosciences, Botolph 124 
Claydon, UK) in 3% acetic acid glacial (Fischer Scientific, Thermo Fischer Scientific, Paisley, 125 
UK). For osteogenic differentiation, GO fibroblasts were plated in 6 well plates (3x104 126 
cells/cm2). After 24 hours, the medium was changed to Osteoblast Differentiation Medium 127 
(ZenBio, NC, USA) and the differentiation was allowed to proceed for 21days, with the medium 128 
changed every 3-4 days. Cells monolayers were fixed in graded ethanol concentrations (25, 50, 129 
75, 100% in PBS) and incubated with alizarin red S (Sigma-Aldrich, Gillingham, UK) at pH 4.2 130 
for 10 minutes to identify calcium deposits. All images were taken using a Leica DMIL 131 
microscope (Leica Microsystems, Milton Keynes, UK) with Nikon DS-Fi1 camera (Kingston 132 
Upon Thames, UK). These experiments were repeated independently 2-3 times.  133 
 134 
Myogenic and neuronal differentiation 135 
GO cells were seeded on glass coverslips (2x103 cells/cm2) in standard medium in 6 well 136 
plates.  After 24 hours, the medium was supplemented with TGF-β1 (100 ng/ml, PeproTech, 137 
London, UK) for 48 hours (myogenic differentiation) or with neuronal differentiation inducer III 138 
(20 µM, Calbiochem, Merck KGaA, Darmstadt, Germany) for 5 days (neurogenic 139 
differentiation). The coverslips were then fixed in 3.7% formaldehyde, permeabilised in 0.5% 140 
Triton-X100 (Sigma-Aldrich, Gillingham, UK), washed with 0.1M glycine, and blocked with 1% 141 
FBS and 1% donkey serum in Tris Buffer Saline 21. Cells were incubated with primary 142 
antibodies against α-smooth muscle actin (α-SMA, mouse, 1:50; Sigma-Aldrich, Gillingham, 143 
UK) and neuron specific β III tubulin (rabbit, 1:200; Abcam, Cambridge, UK), followed by anti-144 
mouse tetramethylrhodamine (TRITC)-conjugated and anti-rabbit fluorescein isothiocyanate 145 
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(FITC)-conjugated secondary antibodies (both donkey, 1:100; Jackson Labs, Maine, USA) 146 
respectively. Following washes, the coverslips were mounted with Fluoroshield mounting 147 
medium with DAPI (Abcam, Cambridge, UK). Cells were imaged using a NIKON Ti-E 148 
microscope with CoolSNAP HQ2 camera (Photometrics, AZ, USA), using a 20X air objective 149 
(20X Plan Fluor ELWD ADM with correction collar). 150 
 151 
Real-time Polymerase Chain Reaction (RT-PCR)  152 
Differentiated HO1, HO2 and HO3 cells (osteogenesis and chondrogenesis as above), matching 153 
undifferentiated control cells grown under the same conditions but in the standard medium, and 154 
cells from standard monolayer cultures were homogenised in 700 µl of Trizol (Thermo Fischer 155 
Scientific, Paisley, UK). RNA was extracted using the miRNeasy kit (QIAGEN, Hilden, 156 
Germany) according to the manufacturer’s instructions. RNA concentration and purity was 157 
analysed using NanoDrop 2000 (Thermo Scientific, DE, USA). 200 ng of RNA was then 158 
reverse-transcribed using QuantiTect Reverse Transcription kit (QIAGEN, Hilden, Germany) 159 
according to the manufacturer’s instructions, except for the incubation time at 42°C, which was 160 
increased from 15 to 30 minutes. 60 µl of water was then added to the reaction, and 5 µl of this 161 
was mixed with 6.25 µl of water, 12.5 µl of TaqMan gene expression master mix (Applied 162 
Biosystems, DE, USA) and 1.25 µl of a primer targeting one of the following sequences: 163 
aggrecan (ACAN, Hs00153936_m1), SOX-9 (SOX9, Hs01001343_g1), osteonectin (SPARC, 164 
Hs00234160_m1), osteocalcin (BGLAP, Hs01587814_g1), Hypoxanthine-guanine 165 
phosphoribosyltransferase (HPRT1, Hs02800695_m1), Splicing factor 3A subunit 1 (SF3A1, 166 
Hs01066327_m1; all from Applied Biosystems, DE, USA).  The real-time PCR settings were as 167 
follows:  50°C for 2 minutes, 95°C for 10 minutes, 40 iterations of 95°C for 15 seconds and 168 
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60°C for 1 minute. Data interpretation was carried out using the comparative ΔCT method 22. 169 
Transcription products were then run in 2% agarose gels with 1% TAE buffer in distilled water. 170 
Band intensities were measured using ImageJ, and the housekeeping genes HPRT1 (for ACAN 171 
and SPARC) or SF3A1 (for SOX9 and BGLAP) were used to normalize the values.  172 
 173 
Statistical analysis 174 
Flow cytometry graphs show mean and SEM for three individual experiments. Statistical 175 
analysis was performed using ANOVA. Pearson product-moment correlation analysis was 176 
performed on averaged flow cytometry results from three separate experiments, and each of the 6 177 
cell lines was shown as a separate data point. Levels of significance were determined using Table 178 
of Critical Values for Pearson’s correlation coefficient. Statistical analysis for RT-PCR 179 
measurements was performed using ANOVA and two-tailed paired student’s t-test. 180 
  181 
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 Results 182 
GO orbital fibroblasts display an MSC-like marker profile 183 
One of the criteria used to define MSCs is expression of CD73, CD105 and CD90 in at 184 
least 95% of cells, and lack of expression of CD14 or CD11b, CD19 or CD79alpha, CD34, 185 
CD45 and HLA-DR in at least 98% of cells 10. We have shown previously that both GO and 186 
control orbital fibroblasts are negative for CD45, but positive for CD90 (57-96 % of the cells), 187 
with varying levels of expression 6. We used here the same fibroblast lines to further analyse the 188 
expression of CD73, CD105, CD14, CD19, CD34 and HLA-DR. In addition, CD221 (IGF-1R) 189 
was used as a positive control/disease marker, as IGF-1R was previously shown to be 190 
overexpressed in GO fibroblasts, underlying some aspects of the disease 23-25.  191 
As expected, a significant proportion of GO fibroblasts expressed CD221 on average, as 192 
opposed to less than 20% for control fibroblasts (Figure 1A, B), and the levels expressed by 193 
positive cells were significantly higher in GO cells (Figure 1C). Control and GO fibroblasts 194 
displayed very high expression levels for positive markers CD73 and CD105 in the majority of 195 
the cells (Figure 1A, B), but both the percentage of positive cells and the geometric mean 196 
fluorescence intensity of the positive cells were significantly higher in GO fibroblasts (Figure 197 
1B,C).  198 
Only a minor fraction of cells expressed CD14 (0-7.4%), CD19 (0-1.6%) and HLA-DR 199 
(0-1.2%) and at levels barely above background. CD34 expression was unexpectedly elevated, 200 
with 64.6% (SEM=4.6) of CO cells and 51.3% (SEM=3.6) of GO cells displaying the marker 201 
(Figure 1A, B), although the levels of expression were significantly lower in GO cells (Figure 202 
1C). 203 
 11
In order to determine the relationship between CD34 and CD221, and positive markers of 204 
MSCs, we analysed separate marker expression using Pearson product-moment correlation 205 
(Figure 2). There was a strong, negative correlation between levels of expression of CD34 and 206 
CD105 (r =-0.81, p<0.05; Figure 2A). Conversely, there was a strong positive correlation 207 
between the percentages of cells expressing CD221 and positive MSC markers CD73 (r=0.96, 208 
p<0.01) and CD105 (r=0.88, p<0.05; Figure 2B). Similarly, levels of the expression of CD73 and 209 
CD105 markers were strongly correlated to CD221 expression levels (r=0.84 and r=0.87 210 
respectively, p<0.05; Figure 2C). Overall, this showed that GO fibroblasts had a marker profile 211 
that more closely resembled a typical MSC profile than that of control orbital fibroblasts, 212 
suggesting that GO fibroblasts may comprise an MSC-like population capable of multi-lineage 213 
differentiation.  214 
 215 
GO orbital fibroblasts undergo lineage specific differentiation 216 
We have previously shown that GO fibroblasts (HO1, HO2, HO3 lines as used here) 217 
undergo adipogenesis, both following standard stimulation with adipogenic differentiation 218 
medium in monolayer cultures, as well as spontaneously (without any chemical stimulation) 219 
when grown within 3 dimensional collagen matrices 6. To further explore the differentiation 220 
potential of GO fibroblasts, we tested the cells for chondrogenic, osteogenic, myogenic and 221 
neurogenic potential. Following osteogenic differentiation for 21 days, alizarin red was used to 222 
stain calcium deposits that characterise bone mineral formations. Clusters of stained deposits 223 
were found in all 3 GO cell lines incubated in osteogenesis differentiation medium (Figure 3, A-224 
C) but not in control medium (Figure 3, D-E). Additionally, the differentiated cells looked more 225 
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irregular, forming clusters of cells with a 3-dimensional aspect as compared to the characteristic 226 
flat, spindle-shaped morphology of the cells in control medium (Figure 3, A-F).  227 
Following chondrogenic differentiation in cell pellets for 21 days, we used alcian blue 228 
staining to evaluate glycosaminoglycan production as a late chondrogenesis marker. Alcian blue 229 
produced a strong blue staining in the pellets incubated in differentiation medium (Figure 3, G-I), 230 
suggesting significant chondrogenic differentiation, whilst only faint blue spots were visible in 231 
the control pellets (Figure 3, J-L). The Alcian blue staining was largely absent when the sections 232 
were treated with hyaluronidase prior to staining (Figure 3, G’-L’), suggesting that most of the 233 
staining in the samples was due to the presence of glycosamiglycans (rather than non specific 234 
binding of the dye to lipids).  235 
Osteogenesis and chondrogenesis were confirmed by analysing the expression of specific 236 
differentiation markers, BGLAP and SPARC for the former, and ACAN and SOX9 for the latter 237 
respectively. Both real-time PCR (Supplementary Table 1) and the subsequent gel 238 
electrophoresis (Figure 4 and Supplementary Figure 3) identified differentiation markers in all 239 
three fibroblasts cell lines. All cells cultured according to the differentiation protocols showed 240 
upregulation of BGLAP (p=0.006) and SOX9 (p=0.05), with upregulation of ACAN seen in 241 
HO1 and HO2, and upregulation of SPARC seen in HO3.  242 
TGF-β is a potent inducer of myogenic differentiation of MSCs 26, 27, and we found that 243 
stimulation of GO cells with TGF-β led to a marked increase in α-SMA expression (marking the 244 
onset of myocyte differentiation), as well as its significant incorporation into actin stress fibres 245 
(Figure 5, A-F). After differentiation towards neuronal lineage using neuronal differentiation 246 
inducer III, the cells adopted a more elongated morphology (Figure 5, G-L), with some of them 247 
displaying long neuron-like protrusions (Figure 5I). However, both differentiated and 248 
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undifferentiated cells expressed the neuron-specific beta-III tubulin marker, suggesting a pre-249 
existing commitment towards a neuronal lineage (Figure 5, G-L).   250 
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Discussion 251 
The presence of stem cells within adipose tissue is well established and this includes 252 
orbital adipose tissue, where pluripotent cells have been identified that display a classical multi-253 
lineage potential as well as the more unusual ability to differentiate into corneal epithelial cells 254 
13, 14, 28. In addition, there is increasing evidence that fibroblasts display characteristics that define 255 
MSCs, including immuno-phenotype and multi-lineage differentiation 29-32, and that differences 256 
between classical MSC and fibroblasts are within variability seen amongst MSC lines of 257 
different topographical origin 30, 33, 34. We have previously shown that primary fibroblasts from 258 
the orbit of patients with active Graves’ disease displayed a dual profibrotic/contractile and 259 
adipogenic phenotype when cultured within 3 dimensional (3D) collagen matrices 6, and 260 
produced hyaluronan when stimulated with IGF1 or patient serum (D. Ezra, unpublished data). 261 
These cells were also largely positive for CD90 and negative for CD45 6, both positive and 262 
negative markers of MSCs respectively 10-12. We thus hypothesized that GO orbital fibroblasts 263 
contain a population of cells capable of pluripotent differentiation, potentially underlying the 264 
multifaceted phenotype of the disease.  265 
We show here that GO fibroblasts fulfil most of the proposed minimal criteria for MSC 266 
identification 10: they are adherent to plastic under normal culture conditions, and express CD90 267 
6, CD73, CD105 whilst lacking the expression of CD45 6, CD14, CD19 and HLA-DR. However, 268 
a significant proportion of both control and GO orbital cells expressed CD34, a commonly used 269 
negative marker of MSCs, albeit to low levels.  Despite being often acknowledged as a negative 270 
marker for MSCs 10, both adipose-derived MSCs (AMSCs) and committed pre-adipocytes have 271 
been shown to express CD34 12. Thus the presence of CD34 positive cells within a putative MSC 272 
compartment in GO fibroblasts may be linked to the cells’ pro-adipogenic phenotype and 273 
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spontaneous adipogenic differentiation potential in 3D cultures 6. In addition, the 274 
presence/absence of CD34 on MSCs may depend on how, and where from, the cells have been 275 
isolated 35-37, and indeed, CD34 was previously found expressed in orbital adipose tissue, 276 
particularly in the nasal fat area 14. Alternatively, CD34 positive cells may comprise a 277 
subpopulation of fibrocytes, having invaded the orbit from the circulation and contributing to the 278 
diversity of the orbital fibroblast phenotype 8, and to the local MSC pool36. Although fibrocytes 279 
are normally CD45 positive and our GO populations have been found largely negative for 280 
CD456, we cannot entirely rule out some fibrocyte involvement as the expression of CD45 in 281 
fibrocytes is known to decrease after they enter the tissue in vivo as well as during culture in 282 
vitro 38. Overall however, when marker profiles were analysed for correlations, the frequency of 283 
the positive MSC markers CD105 and CD73 correlated positively with the presence of CD221 284 
(IGF-1R), a marker that has been implicated in the pathology of the disease24. Conversely, CD34 285 
expression was inversely correlated to the positive markers expression. This suggests that the 286 
increased expression of MSC positive markers and correlated decrease in MSC negative markers 287 
in GO orbital fibroblasts reflect the emergence within these cells of a population with MSC 288 
characteristics that may be linked disease progression.    289 
When probed for their lineage specific differentiation abilities, GO fibroblasts showed 290 
MSC-like pluripotency. In addition to their previously shown ability to differentiate into 291 
adipocytes 5, 6, 9, we show here that GO fibroblasts displayed significant levels of osteogenesis 292 
and chondrogenesis. Both RT-PCR quantitation and gene electrophoresis confirmed the presence 293 
of differentiation markers (BGLAP and SPARC for osteogenesis; ACAN and SOX9 for 294 
chondrogenesis) in all three GO lines, in both cells exposed to the differentiation protocol and 295 
cells grown in control medium. BGLAP and SOX9, which were expressed at lower levels than 296 
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the other markers, were significantly upregulated in differentiated cells, confirming the 297 
differentiation towards osteogenesis and chondrogenesis respectively. A possible explanation for 298 
the lack of significant upregulation of the other markers in response to the differentiation 299 
protocols is the high basal level of expression. As cell density has been reported to play a role in 300 
both osteogenesis 39, 40 and chondrogenesis 41, 42, we additionally tested expression of three of the 301 
markers in cells grown under standard conditions, i.e. as subconfluent monolayers. Again, all 302 
markers tested were present in the cells, but most of them at levels lower than in the cells that 303 
had undergone differentiation (ACAN: p=0.04; BGLAP, SPARC, SOX9: p> 0.05). Therefore, 304 
we propose that GO fibroblasts may constitutively express markers classically considered as 305 
markers for osteo- and chondrogenesis, but a further differentiation procedure may be required to 306 
induce functional differentiation and production of calcium deposits and hyaluronan. Indeed 307 
SPARC expression in both mouse and human fibroblasts has been linked to skin and lung 308 
fibrosis 43, 44, suggesting that constitutive expression of SPARC in GO fibroblasts may be linked 309 
to their pro-fibrotic phenotype. 310 
 311 
Myogenic differentiation was not originally one of the minimal criteria that define MSCs. 312 
Nevertheless, a number of studies have shown that MSCs could differentiate into the myogenic 313 
lineage, including both smooth and striated muscle, under various conditions 45-48. Although both 314 
α-SMA and MyoD have been described as early myogenic markers, there is some evidence that 315 
MyoD expression could be transient 46. In addition, α-SMA has been linked to fibrosis, which 316 
could again be of significant relevance in the pathology of Graves’ orbitopathy. GO cells 317 
displayed minimal expression levels of α-SMA in normal cultures but all three lines showed 318 
significantly elevated levels of α-SMA, as well as its incorporation into strong actin stress fibres, 319 
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denoting a differentiation towards a myofibroblast/myogenic phenotype. This strong response to 320 
TGFβ stimulation may also be linked to the pro-fibrotic phenotype of the cells 6, possibly 321 
underlying some of the fibrotic pathology in GO. The ability of MSCs to differentiate into 322 
neurons is more controversial 49, but we found that GO fibroblasts appear to gain some 323 
morphological characteristics of neuronal cells upon stimulation with neuronal differentiation 324 
inducer III. However, they spontaneously expressed the neuronal marker β-III tubulin with little, 325 
if any, changes following stimulation with neuronal differentiation inducer III. This may be a 326 
reflection of the peculiar embryonic origin of orbital fat, as craniofacial adipose tissue is thought 327 
to originate from the neural crest cells rather than the mesoderm as for the most of the white 328 
adipose tissue 50, 51.    329 
 330 
Overall, our findings suggest that GO orbital fibroblasts populations comprise cells that 331 
broadly fulfil the criteria defining MSCs, and have the potential for multi-lineage differentiation. 332 
Although this study is still preliminary and it is not clear whether the pluripotent cell population 333 
in GO represents true MSCs (with self-renewal potential), progenitors, or a mix of both, the 334 
identification of such cells suggests that they could underlie some of the complexity of the 335 
disease phenotype. Considering the emerging evidence of a role for MSCs in modulating 336 
inflammation, and particularly in the context of autoimmune diseases 52, it is tantalizing to 337 
speculate that MSCs/progenitors could be an important factor controlling disease progression in 338 
GO, as they have been proposed to for other fibrotic diseases 50.   339 
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Figure legends 488 
 489 
Figure 1. GO and control orbital fibroblasts express MSC markers.  The expression of MSC 490 
markers CD105, CD73, CD14, CD19, HLA-DR and CD34 10, as well as CD221 (IGF-1R) was 491 
analysed in GO and control fibroblasts using Flow Cytometry. (A) Representative flow charts for 492 
individual markers in one GO (line HO1) and one control (line CO2) fibroblast line. Grey areas 493 
represent specific marker expression profile, with the percentage of positive cells as indicated. 494 
White areas show the distribution of the fluorescence using non-specific matching IgG isoform 495 
control. (B, C) Percentage of cells expressing the indicated marker (B) and Geometric Mean 496 
Fluorescence Intensity (gMFI) for each marker (C). Shown is the mean +/- SEM for 3 GO and 3 497 
control fibroblast lines, with n=3 for each marker in each cell line. *, statistically significant 498 
difference between control and GO cells (p<0.05).  499 
 500 
Figure 2. MSC marker expression is correlated with disease profile. Pearson product-501 
moment correlation analysis was performed between (A) expression levels (mean gMFI) of 502 
CD34 versus CD73 (circles) and CD105 (triangles); (B), percentage of cells expressing CD221 503 
versus CD73 and CD105; and (C) expression levels of CD221 versus CD73 and CD105. Each 504 
point represents averaged data (n=3) for each control (filled symbols) and GO (empty symbols) 505 
cell line. Statistically significant correlations: * p<0.05, ** p<0.01.  506 
 507 
Figure 3. GO fibroblasts demonstrate osteogenic and chondrogenic lineage differentiation. 508 
GO fibroblasts (lines HO1-3) were induced towards osteogenic (A-C), and chondrogenic (G/G’-509 
I/ I’) differentiation using specific media or kept in control medium under the same conditions 510 
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(“undifferentiated”; D-F and J/J’-L/L’, respectively).  (A-F) Cells were stained with alizarin red 511 
in order to evaluate calcium deposits (brown areas). (G-L’) Cell pellets were stained with Alcian 512 
blue without (G-L) or with (G’-L’) prior treatment with hyaluronidase in order to evaluate 513 
glycosaminoglycan production (blue areas). Scale bar, 10 μm. 514 
 515 
Figure 4. GO fibroblasts express markers of osteogenesis and chondrogenesis. GO 516 
fibroblasts (lines HO1-3) were induced towards osteogenic (A, B), and chondrogenic (C, D) 517 
differentiation (“differentiated”, black bars) or kept in control medium under the same conditions 518 
(“undifferentiated”, grey bars); additionally, cells grown under standard cell culture conditions 519 
were tested (A-C, “standard”, white bars). Expression levels of markers of osteogenesis (BGLAP 520 
and SPARC) and chondrogenesis (ACAN, SOX9) were assessed by semi-quantitative analysis of 521 
agarose gel electrophoresis of RT-PCR products. Shown is the mean +/- SEM, with n=2 for each 522 
marker in each cell line. 523 
 524 
Figure 5. GO fibroblasts demonstrate myogenic and neuronal lineage differentiation. GO 525 
fibroblasts (lines HO1-3) were induced towards myogenic (A-C) and neuronal (G-I) 526 
differentiation using specific media or kept in control medium under the same conditions 527 
(“undifferentiated”; D-F and J-K respectively).  (A-F) Cells were immunostained for α-SMA 528 
(red) and DAPI (blue). (G-L) Cells were immunostained for β-III Tubulin (green) and DAPI 529 
(blue). Scale bar, 100 μm. 530 
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